| Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple … A Palumbo, S Bringhen, D Rossi, M Cavalli, A Larocca, R Ria, M Offidani, ... Journal of Clinical Oncology 28 (34), 5101-5109, 2010 | 532 | 2010 |
| Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial A Palumbo, M Cavo, S Bringhen, E Zamagni, A Romano, F Patriarca, ... Journal of Clinical Oncology 29 (8), 986-993, 2011 | 398 | 2011 |
| Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and … M Cavo, F Gay, M Beksac, L Pantani, MT Petrucci, MA Dimopoulos, ... The Lancet Haematology 7 (6), e456-e468, 2020 | 349 | 2020 |
| Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials S Bringhen, MV Mateos, S Zweegman, A Larocca, AP Falcone, A Oriol, ... Haematologica 98 (6), 980, 2013 | 260 | 2013 |
| Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple … A Palumbo, S Bringhen, A Larocca, D Rossi, F Di Raimondo, V Magarotto, ... Journal of Clinical Oncology 32 (7), 634-640, 2014 | 251 | 2014 |
| Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma P Corradini, M Cavo, H Lokhorst, G Martinelli, C Terragna, I Majolino, ... Blood 102 (5), 1927-1929, 2003 | 233 | 2003 |
| Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates V Montefusco, F Gay, F Spina, R Miceli, M Maniezzo, M Teresa Ambrosini, ... Leukemia & lymphoma 49 (11), 2156-2162, 2008 | 229 | 2008 |
| Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients A Palumbo, F Gay, P Falco, C Crippa, V Montefusco, F Patriarca, ... Journal of Clinical Oncology 28 (5), 800-807, 2010 | 196 | 2010 |
| Real-time quantitation of minimal residual disease in inv (16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state S Buonamici, E Ottaviani, N Testoni, V Montefusco, G Visani, F Bonifazi, ... Blood, The Journal of the American Society of Hematology 99 (2), 443-449, 2002 | 178 | 2002 |
| Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study S Bringhen, MT Petrucci, A Larocca, C Conticello, D Rossi, V Magarotto, ... Blood, The Journal of the American Society of Hematology 124 (1), 63-69, 2014 | 161 | 2014 |
| Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma A Vacca, C Scavelli, V Montefusco, G Di Pietro, A Neri, M Mattioli, ... Journal of clinical oncology 23 (23), 5334-5346, 2005 | 157 | 2005 |
| Timing the initiation of multiple myeloma EH Rustad, V Yellapantula, D Leongamornlert, N Bolli, G Ledergor, ... Nature communications 11 (1), 1917, 2020 | 146 | 2020 |
| Efficacy of carfilzomib lenalidomide dexamethasone (KRd) with or without transplantation in newly diagnosed myeloma according to risk status: Results from the FORTE trial. F Gay, C Cerrato, MT Petrucci, R Zambello, B Gamberi, S Ballanti, ... Journal of Clinical Oncology 37 (15_suppl), 8002-8002, 2019 | 129 | 2019 |
| Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma N Van De Donk, N Kröger, U Hegenbart, P Corradini, JF San Miguel, ... Bone marrow transplantation 37 (12), 1135-1141, 2006 | 126 | 2006 |
| Double autologous stem cell transplantation significantly prolongs progression-free survival and overall survival in comparison with single autotransplantation in newly … M Cavo, FM Gay, F Patriarca, E Zamagni, V Montefusco, L Dozza, M Galli, ... Blood 130, 401, 2017 | 116 | 2017 |
| Superior complete response rate and progression-free survival after autologous transplantation with up-front velcade-thalidomide-dexamethasone compared with thalidomide … M Cavo, P Tacchetti, F Patriarca, MT Petrucci, L Pantani, M Ceccolini, ... Blood 112 (11), 158, 2008 | 113 | 2008 |
| Identification of four new translocations involving FGFR1 in myeloid disorders J Sohal, A Chase, S Mould, M Corcoran, D Oscier, S Iqbal, S Parker, ... Genes, Chromosomes and Cancer 32 (2), 155-163, 2001 | 110 | 2001 |
| Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study A Larocca, V Montefusco, S Bringhen, D Rossi, C Crippa, R Mina, M Galli, ... Blood, The Journal of the American Society of Hematology 122 (16), 2799-2806, 2013 | 105 | 2013 |
| Bortezomib (Velcade (R))-thalidomide-dexamethasone (VTD) vs thalidomide-dexamethasone (TD) in preparation for autologous stem-cell (SC) transplantation (ASCT) in newly … M Cavo, F Patriarca, P Tacchetti, M Galli, G Perrone, MT Petrucci, A Brioli, ... Blood 110 (11), 30A-30A, 2007 | 102 | 2007 |
| Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma V Magarotto, S Bringhen, M Offidani, G Benevolo, F Patriarca, R Mina, ... Blood, the Journal of the American Society of Hematology 127 (9), 1102-1108, 2016 | 98 | 2016 |
